(MCK) McKesson - Overview

Sector: Healthcare | Industry: Medical Distribution | Exchange: NYSE (USA) | Market Cap: 91.424m USD | Total Return: 5.4% in 12m

Pharmaceuticals, Medical Supplies, Logistics, Healthcare Software

Total Rating 47

Safety 62

Buy Signal -0.27

Medical Distribution
Industry Rotation: +2.7

Market Cap: 91.4B
Avg Turnover: 709M

Risk 3d forecast

Volatility24.0%

VaR 5^th Pctl4.03%

VaR vs Median2.24%

Reward TTM

Sharpe Ratio0.17

Rel. Str. IBD20.2

Rel. Str. Peer Group28.4

Character TTM

Beta-0.247

Beta Downside-0.254

Hurst Exponent0.449

Drawdowns 3y

Max DD27.17%

CAGR/Max DD0.91

CAGR/Mean DD5.04

EPS (Earnings per Share)

EPS CAGR: 14.87%
EPS Trend: 93.5%

Last SUE: 0.82
Qual. Beats: 0

Revenue

Rev. CAGR: 14.81%
Rev. Trend: 99.5%

Last SUE: -1.90
Qual. Beats: -1

Warnings

Altman Z'' 0.92 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: MCK McKesson

McKesson Corporation (NYSE: MCK) is a diversified healthcare services leader specializing in pharmaceutical distribution and health information technology. Founded in 1833, the company operates through four primary segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. Its core business model functions as a critical link in the healthcare supply chain, managing the logistics and wholesale distribution of branded, generic, and specialty drugs to retail pharmacies and clinical providers.

The company operates within the Health Care Distributors sub-industry, a sector characterized by high-volume, low-margin operations that benefit from significant economies of scale. Beyond physical distribution, McKesson provides practice management and clinical support to specialty providers, particularly in oncology, and offers technology solutions that integrate pharmacy benefit managers with biopharma partners to streamline medication access.

Investors looking for deeper insights into these operational segments may find further value in the data available at ValueRay.

The Medical-Surgical Solutions segment extends the companys reach into non-acute settings, supplying physician offices and long-term care facilities with essential medical supplies and biomedical maintenance. Internationally, McKesson maintains a presence through wholesale and retail pharmacy networks, providing manufacturers with logistics and information technology infrastructure across global markets.

Headlines to Watch Out For

Specialty pharmaceutical and oncology distribution growth drives high-margin revenue expansion
Biosimilar adoption rates influence generic drug portfolio profitability and market share
Prescription Technology Solutions segment growth accelerates high-value software and services revenue
Opioid litigation settlement payments affect long-term cash flow and capital allocation
Government reimbursement policy changes impact medical-surgical and pharmaceutical distribution margins

Piotroski VR‑10 (Strict) 5.5

Net Income: 4.76b TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.26 > 1.0
NWC/Revenue: -2.43% < 20% (prev -1.73%; Δ -0.70% < -1%)
CFO/TA 0.07 > 3% & CFO 6.16b > Net Income 4.76b
Net Debt (4.64b) to EBITDA (7.20b): 0.64 < 3
Current Ratio: 0.85 > 1.5 & < 3
Outstanding Shares: last quarter (122.7m) vs 12m ago -2.54% < -2%
Gross Margin: 3.61% > 18% (prev 0.03%; Δ 357.2% > 0.5%)
Asset Turnover: 512.4% > 50% (prev 477.8%; Δ 34.57% > 0%)
Interest Coverage Ratio: 26.20 > 6 (EBITDA TTM 7.20b / Interest Expense TTM 247.0m)

Altman Z'' 0.92

A: -0.12 (Total Current Assets 57.21b - Total Current Liabilities 67.02b) / Total Assets 82.32b
B: 0.27 (Retained Earnings 22.29b / Total Assets 82.32b)
C: 0.08 (EBIT TTM 6.47b / Avg Total Assets 78.73b)
D: 0.25 (Book Value of Equity 20.84b / Total Liabilities 83.16b)
Altman-Z'' Score: 0.92 = BB

Beneish M -2.91

DSRI: 0.97 (Receivables 27.98b/25.64b, Revenue 403.43b/359.05b)
GMI: 0.95 (GM 3.61% / 3.41%)
AQI: 1.20 (AQ_t 0.25 / AQ_t-1 0.21)
SGI: 1.12 (Revenue 403.43b / 359.05b)
TATA: -0.02 (NI 4.76b - CFO 6.16b) / TA 82.32b)
Beneish M-Score: -2.91 (Cap -4..+1) = A

What is the price of MCK shares? As of May 21, 2026, the stock is trading at USD 754.68 with a total of 779,842 shares traded.
Over the past week, the price has changed by +2.37%, over one month by -12.15%, over three months by -20.28% and over the past year by +5.35%.

Is MCK a buy, sell or hold? McKesson has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy MCK.

StrongBuy: 10
Buy: 3
Hold: 3
Sell: 1
StrongSell: 0

What are the forecasts/targets for the MCK price?

Analysts Target Price	949.7	25.8%

McKesson (MCK) - Fundamental Data Overview as of 18 May 2026

P/E Trailing = 19.8014
P/E Forward = 16.6389
P/S = 0.2266
P/B = 5.0435
P/EG = 0.8948
Revenue TTM = 403.43b USD
EBIT TTM = 6.47b USD
EBITDA TTM = 7.20b USD
Long Term Debt = 5.42b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.55b USD (from shortTermDebt, last quarter)
Debt = 8.61b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.64b USD (from netDebt column, last quarter)
Enterprise Value = 96.06b USD (91.42b + Debt 8.61b - CCE 3.98b)
Interest Coverage Ratio = 26.20 (Ebit TTM 6.47b / Interest Expense TTM 247.0m)
EV/FCF = 16.18x (Enterprise Value 96.06b / FCF TTM 5.94b)
FCF Yield = 6.18% (FCF TTM 5.94b / Enterprise Value 96.06b)
FCF Margin = 1.47% (FCF TTM 5.94b / Revenue TTM 403.43b)
Net Margin = 1.18% (Net Income TTM 4.76b / Revenue TTM 403.43b)
Gross Margin = 3.61% ((Revenue TTM 403.43b - Cost of Revenue TTM 388.88b) / Revenue TTM)
Gross Margin QoQ = 4.20% (prev 3.47%)
Tobins Q-Ratio = 1.17 (Enterprise Value 96.06b / Total Assets 82.32b)
Interest Expense / Debt = 0.71% (Interest Expense 61.0m / Debt 8.61b)
Taxrate = 12.71% (270.0m / 2.12b)
NOPAT = 5.65b (EBIT 6.47b * (1 - 12.71%))
Current Ratio = 0.85 (Total Current Assets 57.21b / Total Current Liabilities 67.02b)
Debt / Equity = -3.97 (negative equity) (Debt 8.61b / totalStockholderEquity, last quarter -2.17b)
Debt / EBITDA = 0.64 (Net Debt 4.64b / EBITDA 7.20b)
Debt / FCF = 0.78 (Net Debt 4.64b / FCF TTM 5.94b)
Total Stockholder Equity = -928.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.05% (Net Income 4.76b / Total Assets 82.32b)
RoE = -513.1% (negative equity) (Net Income TTM 4.76b / Total Stockholder Equity -928.0m)
RoCE = 143.9% (EBIT 6.47b / Capital Employed (Equity -928.0m + L.T.Debt 5.42b))
RoIC = 99.19% (NOPAT 5.65b / Invested Capital 5.70b)
WACC = 4.72% (E(91.42b)/V(100.04b) * Re(5.11%) + D(8.61b)/V(100.04b) * Rd(0.71%) * (1-Tc(0.13)))
Discount Rate = 5.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -100.00 | Cagr: -3.62%
[DCF] Terminal Value 86.75% ; FCFF base≈5.65b ; Y1≈5.89b ; Y5≈6.80b
[DCF] Fair Price = 1.64k (EV 201.21b - Net Debt 4.64b = Equity 196.57b / Shares 120.2m; r=6.0% [WACC]; 5y FCF grow 4.56% → 3.0% )
EPS Correlation: 93.51 | EPS CAGR: 14.87% | SUE: 0.82 | # QB: 0
Revenue Correlation: 99.45 | Revenue CAGR: 14.81% | SUE: -1.90 | # QB: -1
EPS current Quarter (2026-06-30): EPS=9.58 | Chg30d=+0.30% | Revisions=+11% | Analysts=14
EPS next Quarter (2026-09-30): EPS=10.79 | Chg30d=-0.58% | Revisions=+11% | Analysts=14
EPS current Year (2027-03-31): EPS=44.26 | Chg30d=+0.29% | Revisions=+14% | GrowthEPS=+13.2% | GrowthRev=+7.0%
EPS next Year (2028-03-31): EPS=50.32 | Chg30d=+0.87% | Revisions=+43% | GrowthEPS=+13.7% | GrowthRev=+7.5%
[Analyst] Revisions Ratio: +43%